Analyst Ratings For
Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Today,
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) stock was downgraded by Maxim Group from Buy to Hold.
There are 2 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is Buy with a consensus target price of $3.70 per share, a potential 487.30% upside.
Some recent analyst ratings include
- 11/25/2019-
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) gets downgraded to Hold by Maxim Group
- 7/23/2019-
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) gets upgraded to Neutral by B. Riley- 7/2/2019-
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has coverage initiated with a Buy rating- On 11/18/2019 David J Marguglio, SVP, sold 8,283 with an average share price of $0.87 per share and the total transaction amounting to $7,206.21.
- On 11/18/2019 Dennis J Phd Carlo, CEO, sold 10,760 with an average share price of $0.84 per share and the total transaction amounting to $9,038.40.
- On 11/18/2019 Karen K Daniels, VP, sold 5,421 with an average share price of $0.83 per share and the total transaction amounting to $4,499.43.
- On 11/18/2019 Robert O Hopkins, CFO, sold 7,347 with an average share price of $0.83 per share and the total transaction amounting to $6,098.01.
- On 11/18/2019 Ronald B Moss, Insider, sold 8,448 with an average share price of $0.85 per share and the total transaction amounting to $7,180.80.
- On 8/19/2019 David J Marguglio, SVP, sold 8,109 with an average share price of $1.10 per share and the total transaction amounting to $8,919.90.
- On 8/19/2019 Dennis J Phd Carlo, CEO, sold 10,477 with an average share price of $1.06 per share and the total transaction amounting to $11,105.62.
Recent Trading Activity for
Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Shares ofAdamis Pharmaceuticals Corp closed the previous trading session at with shares trading hands. - 7/23/2019-